Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2023 · 10-K
Revenue$176.00K$176.00K+351.3% vs Q4 2022 Net Income-$12.23M-$12.23MN/M vs Q4 2022 EPS, diluted—
Operating Income-$12,239,000N/M Operating Cash Flowderived-$7,473,600N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,789,600N/M Margins · derivedOperating margin-6954.0%+35848.6 pt vs Q4 2022
Net margin-6947.2%+35842.6 pt vs Q4 2022
ended Mar 31, 2023 · filed Jun 28, 2023 · 89 d after period end